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GLEEVEC AS THERAPY FOR RELAPSED CHRONIC MYELOID LEUKEMIA
(CML) AND Ph ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AFTER
BONE MARROW TRANSPLANTATION (BMT)
Funke, V.M.1, Samir, N.1, Michel, O.M.1, Henrique, B.2, Nelma, C.2,
Fernanda, L.2, Nelson, H.3, Marci, P.3, de Lima, D.H.1,
Setubal, D.C.1, Jefferson, R.1, Bonﬁm, C.M.1, Bitencourt, M.A.1,
de Medeiros, C.R.1, Zanis, J.1, Pasquini, R.1 1Hospital de Clı´nicas-
Federal University of Parana, Curitiba, Parana, Brazil; 2Hospital das
Clı´nicas-Federal University of Minas Gerais, Belo-Horizonte, MG, Bra-
zil; 3Hospital Israelita Albert Einstein, Sa˜o Paulo, Brazil.
CML relapsed after BMT has been treated with donor lympho-
cyte infusions (DLI), with responses achieving 60-70% of patients,
and even better results in cytogenetic or molecular relapse. How-
ever, complications as chronic GVHD and myelosuppression can
be a problem, specially on those who receive larger DLI doses. We
report 33 patients who received Gleevec as therapy for relapse after
BMT (32 CML and 1 Ph positive ALL). Patient characteristics at
study entry: age: 13-56 (median [M] 38 y); sex M/F: 18/15; BMT
type: allo: 32 pts, syngeneic: 1 pt. Time from BMT to relapse:
0-122 mo (M 16 mo). Relapse was hematologic in 30 and cytoge-
netic in 3 patients. Phase at hematologic relapse: CP-14 pts, AP-11
pts and BC-5 pts; cytogenetics: 100% Ph—30 pts, 10-30% Ph—2
pts, Ph negative (neg.)—1 pt., clonal evolution: 7 patients. VNTR
was available at the beginning of therapy in 16 pts: 10-35% donor
in 11 pts, 0% donor in 3 pts and 95% donor in 2 pts. Dose: 600 mg
QD in 16 pts, 400 mg QD—17 pts. Previous DLI: 14 pts (5 as
concomitant therapy). Results: Therapy duration: 7-1795 d (M
365 d); 28 (84%) pts have reached complete hematologic response
(CHR). Five (15%) pts have relapsed after a initial response—1 on
BC, the patient with Ph positive ALL and 3 pts on AP. Time to
CHR: 7-60 d (M 28 d). Cytogenetic response was available for 25
pts, being complete in 16 (48%), partial in 2 and absent in 7 pts.
Molecular data by competitive Q-PCR were available in 21 pa-
tients, of whom 10 had major molecular responses (3-log reduction
at the BCR-ABL/ABL ratio). In 6 (18%) patients BCR-ABL was
negative by nested PCR. 9 pts have improved quimerism on
VNTR analysis to more than 95% donor cells after Gleevec ther-
apy. Hematologic toxicity grade II-IV was observed in 21 pts
(63%) pts. Eleven pts developed grade IV neutropenia with a
duration of 0-8 mo (M 2 mo). Five pts developed non-hematologic
toxicity grade III-IV. Dose was held in 4 pts, increased in 6 pts and
reduced in 11 pts. Only two pts developed skin and liver chronic
GVHD, and those have reached CHR and CCR. Two patients
who had c-GVHD before therapy with imatinib did not ﬂare.
Estimated 5y OS is 67%. Conclusions: 1) Gleevec can be used
safely as therapy for BMT relapse, with durable cytogenetic and
molecular responses in chronic phase; 2) complete quimerism is
often reestablished by Gleevec therapy after allogeneic BMT; 3)
increased incidence of GVHD was not observed in this group of
patients.
59
T-CELL SIGNALING IN ALLOGENEIC BONE MARROW TRANSPLANTA-
TION
Lu, S.X., Chow, M.Y., Hubbard, V.M., Suh, D.Y., Kim, T.D.,
Kochman, A., Zakrzewski, J., Cabrera-Perez, J., Alpdogan, O.,
van den Brink, M.R.M. Memorial Sloan-Kettering Cancer Center, New
York, NY.
We examined the signaling proﬁles of T cells in murine alloge-
neic bone marrow transplantation with a novel high-throughput
technique to analyze activation of signaling pathways by ﬂow cy-
tometry. We ﬁrst studied normal splenic, liver, and peripheral
lymph node (PLN) T cells. Relative to naive CD4 and CD8 cells,
effector and memory cells displayed nearly global increases in
activation of signaling pathways including MEK1/2 and PKC
(both up 10-fold), and S6 ribosomal protein (6 fold) (Table 1).
In the thymus, there was a general lack of signaling activity in
CD4CD8 cells, and these did not respond to cytokines. By
contrast, CD4CD8 (DN) cells of the DN1 and DN2 stage had
the greatest signaling activity of all subsets. CD4, CD8, and
DN cells responded to the cytokines IL-7 and IL-15 by phosphor-
ylating STAT-5A (10 fold). We then studied alloreactive and
homeostatically proliferating T cells by infusion of CFSE labeled
cells into irradiated hosts. We noted a gradual and global increase
in signaling activity with each cell division in the spleen, liver, and
PLN. Molecules that were phosphorylated included c-Raf,
MEK1/2, ERK1/2, Akt, STAT-1, STAT-3, STAT-4, and S6 ri-
bosomal protein. Tacrolimus and cyclosporin inhibited both cell
cycling and increases in signaling. We deﬁned slow-cycling cells as
homeostatically expanding and fast-cycling cells as alloreactive, and
found a distinct signaling pattern in homeostatically expanding T
cells, with lower levels of MAP kinase pathway activity and STAT
pathway activity. We hypothesize that this difference can be at-
tributed to strong IL-2 and TCR signaling in alloreactive cells
through the MAP kinases, Akt and STAT-3, by IFN for STAT-1,
and by IL-12 for STAT-4. In the setting of T-cell depleted bone
marrow transplantation, we found in several models that bone
marrow-derived splenic T cells had signaling levels generally com-
parable with that of the naive populations in a normal spleen, but
with a deﬁciency in STAT-3 phosphorylation. In the thymus, we
observed a defect in Akt signaling in all subsets relative to signaling
levels in the normal thymus, with up to 100-fold decreases. The
defect persisted up to day 28 post-transplant. We conclude that the
high-throughput analysis of signaling activity in T cells during
allogeneic BMT allows for the deﬁnition of distinct signaling
proﬁles. These signaling signatures can be used for the develop-
ment of targeted therapies to enhance or inhibit speciﬁc T cell
subsets.
Table 1. Signaling in the C57BL/6 Spleen
CD4 CD8
Naive
(CD44lo
CD62Lhi)
Effector
(CD44hi
CD62Llo)
Memory
(CD44hi
CD62Lhi)
Naive
(CD44lo)
Effector/
Memory
(CD44hi)
c-Raf (pS259) 1 2.2 1.8 1 1.2
MEK 1/2 (pS217/pS221) 1 2.7 9.7 1 2.2
ERK 1/2 (pT202/pY204) 1 1.6 1.8 1 1.2
JNK (pT180/pY182) 1 1.1 6.5 1 2.3
pan-p38 (pT180/pY182) 1 2.1 3.0 1 1.8
pan-Akt (pT308) 1 2.1 3.8 1 1.4
pan-Akt (pS473) 1 2.6 3.9 1 1.7
Pan-PKC (II pS660) 1 2.7 10.1 1 1.4
STAT-1 (pY701) 1 0.9 6.3 1 2.4
STAT-3 (pY705) 1 1.4 1.8 1 1.3
STAT-3 (pS727) 1 1.2 1.3 1 1.3
STAT-4 (pY693) 1 2.0 2.3 1 1.2
STAT-5A (pY694) 1 1.3 1.7 1 1.3
S6 ribosomal protein
(pS235/pS236)
1 3.0 6.3 1 1.8
Histone H2B (pS14) 1 2.6 4.2 1 1.8
PIP2 1 1.3 0.4 1 0.6
Ratio of activation (phosphorylation) of signaling molecules in
effector or memory CD4 or CD8 cells compared with corre-
sponding naive CD4 or CD8 cells.
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FLUDARABIN AND RABBIT ANTITHYMOCYTE GLOBULIN AS CONDI-
TIONING FOR REPEAT TRANSPLANTATION AFTER PRIMARY AND SEC-
ONDARY GRAFT FAILURE FOLLOWING UNRELATED HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Baurmann, H., Taube, R., Dogan, K., Bertelsmann, A., Schleuning, M.,
Schwerdtfeger, R. BMT Center, Deutsche Klinik fuer Diagnostik, Wies-
baden, Germany.
Introduction: Primary or secondary graft failure is a serious
complication of allogeneic stem cell transplantation. The underly-
ing mechanism may be rejection mediated by recipient immuno-
competent cells or loss of donor hematopoiesis due to other, often
unknown causes. We here report on the results of second trans-
plantation in 8 patients reconditioned with ﬂudarabin and ATG in
which an immunological cause of graft failure was either proven or
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